Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

DNMT3A mutation + FLT3-ITD mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

TET2 deletion + DNMT3A mutation (4)

NUP98-NSD1 fusion + FLT3-ITD mutation (3)

CD123 positive + FLT3-ITD mutation (1)

CSK overexpression + FLT3-ITD mutation (1)

EPHB2 overexpression + FLT3-ITD mutation (1)

FLT3 A848P + MLL-MLLT3 fusion (1)

FLT3 wild-type + TP53 mutation (1)

FLT3-ITD mutation + MLL fusion + TP53 mutation (1)

FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression (1)

FLT3-ITD mutation + RIPK1 expression (1)

FLT3-ITD mutation + SKI overexpression (1)

HCK overexpression + FLT3-ITD mutation (1)

HLF overexpression + FLT3-ITD mutation (1)

KAT6A-CREBBP fusion + FLT3-TKD mutation (1)

LYN overexpression + FLT3-ITD mutation (1)

miR-155 deletion + FLT3-ITD mutation (1)

ALK positive + DNMT3A N403Tfs* (1)

TET2 deletion + DNMT3A mutation (4)

NUP98-NSD1 fusion + FLT3-ITD mutation (3)

CD123 positive + FLT3-ITD mutation (1)

CSK overexpression + FLT3-ITD mutation (1)

EPHB2 overexpression + FLT3-ITD mutation (1)

FLT3 A848P + MLL-MLLT3 fusion (1)

FLT3 wild-type + TP53 mutation (1)

FLT3-ITD mutation + MLL fusion + TP53 mutation (1)

FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression (1)

FLT3-ITD mutation + RIPK1 expression (1)

FLT3-ITD mutation + SKI overexpression (1)

HCK overexpression + FLT3-ITD mutation (1)

HLF overexpression + FLT3-ITD mutation (1)

KAT6A-CREBBP fusion + FLT3-TKD mutation (1)

LYN overexpression + FLT3-ITD mutation (1)

miR-155 deletion + FLT3-ITD mutation (1)

ALK positive + DNMT3A N403Tfs* (1)

›

DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3	cytarabine + idarubicin Resistant: C3 – Early Trials cytarabine + idarubicin Resistant : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4	venetoclax Sensitive: C4 – Case Studies venetoclax Sensitive : C4